Recent news on Aceon

Hypertension drugs offer a double whammy  -  May 7, 2007
News-Medical.net,...such as captopril (Capoten), fosinopril (Monopril), lisinopril (Prinivil or Zestril), perindopril (Aceon), ramipril (Altace) and trandolapril (Mavik).

Some High Blood Pressure Drugs may Help Reduce Dementia Risk  -  May 7, 2007
MedIndia,Centrally acting drugs include captropril (Capoten®), fosinopril (Monopril®), lisinopril (Prinivil® or Zestri®), perindopril (Aceon®), ramipril (Altace®)

Some Blood Pressure Drugs Fight Dementia  -  May 7, 2007
NBC4.TV,Centrally acting drugs differ from others because the cross the blood-brain barrier. Drugs in the class include Capoten, Monopril, Prinivil, Zestri, Aceon,

Some heart drugs may slow mental decline with age  -  May 7, 2007
Scientific AmericanCentrally acting ACE inhibitors include captopril (Capoten), fosinopril (Monopril), lisinopril (Prinivil or Zestril), perindopril (Aceon), ramipril (Altace)

BP drugs may cut Alzheimer risk  -  May 7, 2007
Times of India,Centrally acting drugs include captropril (Capoten), fosinopril (Monopril), lisinopril (Prinivil or Zestri), perindopril (Aceon), ramipril (Altace) and

AGS: Centrally Active ACE Inhibitors May Slow Cognitive Decline  -  May 7, 2007
Psychiatric Times,Those agents are captopril (Capotel), fosinopril (Monopril), lisinopril (Prinivil or Zestril), perindopril (Aceon), ramipril (Altace) and trandolapril

Centrally active ACE inhibitors linked to lower rates of mental ...  -  May 7, 2007
TheHeart.Org,AstraZeneca), perindopril (Aceon, Solvay Pharmaceuticals), ramipril (Altace, King Pharmaceuticals), and trandolapril (Mavik, Abbott Laboratories),

Some Blood Pressure Drugs Fight Dementia  -  May 7, 2007
WAPT,Drugs in the class include Capoten, Monopril, Prinivil, Zestri, Aceon, Altace and Mavik. Distributed by Internet Broadcasting.

ACE Inhibitors Linked to Lower Rates of Mental Decline in Elderly  -  May 5, 2007
Medscape (subscription)Centrally active ACEIs, such as captropril (Capoten), fosinopril (Monopril), lisinopril (Prinivil or Zestril), perindopril (Aceon), ramipril (Altace),

CV Therapeutics Reports 2007 First Quarter Financial Results  -  Apr 24, 2007
PR Newswire (press release),...which consisted of $4.4 million in collaborative research revenue and $0.7 million in co-promotion revenue related to ACEON(R) (perdindopril erbumine)

CV Therapeutics Reports 2007 First Quarter Financial Results  -  Apr 24, 2007
Earthtimes.org...which consisted of $4.4 million in collaborative research revenue and $0.7 million in co-promotion revenue related to ACEON(R) (perdindopril erbumine)

New drug battles 'silent killer'  -  Mar 7, 2007
DrugResearcher.com,Mavik (trandolapril) is due off patent later this year with Solvay Pharmaceuticals' Aceon/Coversyl (perindopril) due to lose patent protection in 2009.

CV Therapeutics Reports 2006 Fourth Quarter and Full Year ...  -  Feb 9, 2007
PharmaLive.com (press release),Co-promotion revenue represents the Company's share of ACEON(R) product revenues that exceeded the baseline specified in the amended co-promotion agreement

BUY ALTACE, Altace Online, Altace Cheap  -  Dec 25, 2006
Indymedia Colombia,Although oral contraceptives have other effects Angiotensin-converting enzyme (ACE) inhibitors Accupril, Aceon, Altace, Capoten, Lotensin, Mavik, Monopril,

BUY ALTACE, Altace Online, Altace Cheap  -  Dec 25, 2006
Indymedia Colombia,Although oral contraceptives have other effects Angiotensin-converting enzyme (ACE) inhibitors Accupril, Aceon, Altace, Capoten, Lotensin, Mavik, Monopril,

CV Therapeutics to Stop Selling Aceon  Oct 11, 2006
...said Wednesday that it will no longer help sell the high blood pressure medication Aceon with Solvay Pharmaceuticals Inc. The company ... -Houston Chronicle, CV Therapeutics ends co-promotion of Aceon  Oct 11, 2006
By Victoria Harrison. CV Therapeutics said that it has terminated its co-promotion agreement with Solvay Pharmaceuticals over the drug Aceon. ... -Pharmaceutical Business Review CV Therapeutics To End Co-promotion Deal For ACEON Tablets With ...  Oct 11, 2006
...under the companies' co-promotion agreement for ACEON or perindopril erbumine Tablets. CV Therapeutics stated that within the next ... -Trading Markets, CV ends co-promotion of Aceon  Oct 11, 2006
11 (UPI) -- CV Therapeutics said Wednesday it planned to end its co-promotion of Aceon with Solvay Pharmaceuticals so it could focus on Ranexa. ... -United Press International CV Therapeutics Ending Co-Promotion of ACEON(R) (perindopril ...  Oct 11, 2006
...of the co-promotion agreement. CV Therapeutics does not expect to recognize further revenues from ACEON. "We are excited to focus ... -Earthtimes.org CV Therapeutics Ending Co-Promotion of ACEON(R) (perindopril ...  Oct 11, 2006
...a notice of termination under the companies' co-promotion agreement for ACEON® (perindopril erbumine) Tablets. Over the next several ... -Yahoo! News (press release) CV Therapeutics Reports 2006 Third Quarter Financial Results  Oct 31, 2006
There was no co-promotion revenue recognized for the quarter ended September 30, 2006 related to sales of ACEON(R) (perindopril erbumine) Tablets since ACEON(R ... -MSN Money Waiting for CVT's Trial Results  Nov 1, 2006
The other mildly interesting news for the quarter is that CVT stopped using its over 200-person sales force to co-market Solvay's ACE inhibitor, Aceon. ... -Motley Fool CV Therapeutics Terminates Co-Promotion Deal With Solvay Pharma ...  Oct 11, 2006
...under the companies' co-promotion agreement for Aceon tablets. CV Therapeutics noted that it would conclude its promotion of Aceon ... -Trading Markets, CV Therapeutics says to end co-promotion of hypertension drug  Oct 11, 2006
...to terminate an agreement to co-promote hypertension drug Aceon. ... CV Therapeutics said it will conclude its promotion of Aceon over the next several weeks. ... -Reuters Market Report -- In Play (WIRES)  Oct 11, 2006
CV Therapeutics (CVTX) announces that it has sent Solvay Pharmaceuticals a notice of termination under the cos' co-promotion agreement for Aceon Tablets. ... -MSN Money Speaking of generics  Oct 25, 2006
Upcoming generics These brand-name drugs are expected to become generic in coming years (name of brand-name drug and when its patent expires): Aceon, Feb. ... -Monterey County Herald, International Approvals: Coversyl, Exjade, and Loramyc  Oct 27, 2006
In the United States, perindopril tablets are marketed as Aceon by Solvay Pharmaceuticals, Inc, and CV Therapeutics, Inc, under license from Servier ... -Medscape (subscription) (PRN) - Micrel Introduces New Ultra-Low Dropout Regulator ...  Oct 11, 2006
...[+]. (PRN) - CV Therapeutics Ending Co-Promotion of ACEON(R) (perindopril erbumine) Tablets ... [+. PRN) - Demand for GridApp Systems 'Ready. Set. ... -Bolsamania.com, New hypertension pills cut diabetes risk by third  Sep 6, 2006
...with a combination of Pfizer Inc.'s Norvasc and Coversyl, which was developed by France's Servier and is marketed in the United States as Aceon by Solvay SA ... -Reuters

Hypertension pills cut diabetes risk  Sep 6, 2006
...and a diuretic with a combination of Pfizer’s Norvasc and Coversyl, which was developed by France's Servier and is marketed in the US as Aceon by Solvay SA ... -Trade Arabia

Servier Drug Has Some Benefits For Elderly Patients -Study  Sep 3, 2006
...generic name is perindopril, was developed by Servier, France's second largest pharmaceutical company, and is marketed in the US under the Aceon brand name by ... -Easy Bourse (Communiqués de presse)

CV Therapeutics Announces Seven Abstracts Accepted for ...  Aug 24, 2006
CV Therapeutics' approved products include Ranexa(R) (ranolazine extended- release tablets) and ACEON(R) (perindopril erbumine) Tablets. ... -PR Newswire

New hypertension pills cut diabetes risk by third  Sep 6, 2006
Inc.'s (PFE.N: Quote, Profile, Research) Norvasc and Coversyl, which was developed by France's Servier and is marketed in the United States as Aceon by Solvay ... -Reuters

-- Coversyl(R) in PEP-CHF Trial, is the First Agent to Demonstrate ...  Sep 3, 2006
PREXANIL(R), PREXUM(R), COVERENE(R), COVERSUM(R), PROCAPTAN(R) and marketed by Solvay Pharmaceutical and CV Therapeutics under the trade name of ACEON(R) in ... -Europa Press

ESC/WCC: Fasting Plasma Glucose Best Predictor of Diabetes Risk  Sep 6, 2006
19,342-patient trial, which were reported last year at this meeting, indicated that combination therapy with Norvasc (amlodipine) and Aceon (perindopril) was ... -MedPage Today

CV Therapeutics stock hits 52-week low on new public offering  Aug 14, 2006
...of cardiovascular diseases. Its approved products include Ranexa, which it started marketing in the spring, and Aceon. Ranexa is ... -San Jose Business Journal

CV Therapeutics Brings In $85.5M Via Public Offering  Aug 16, 2006
The company's second marketed product, ACEON (perindopril erbumine tablets), is approved to reduce the risk of cardiovascular mortality or nonfatal myocardial ... -BioWorld Online

CV Therapeutics Announces Exercise of Over-Allotment Option of ...  Aug 18, 2006
CV Therapeutics' approved products include Ranexa® (ranolazine extended- release tablets) and ACEON® (perindopril erbumine) Tablets. ... -Yahoo! News

CV Therapeutics Announces Exercise of Over-Allotment Option of ...  Aug 18, 2006
CV Therapeutics' approved products include Ranexa(R) (ranolazine extended- release tablets) and ACEON(R) (perindopril erbumine) Tablets. ... -Genetic Engineering News

CV Therapeutics Reports 2006 Second Quarter Financial Results  Aug 3, 2006
...outside contract expenses for the regadenoson development program and lower marketing expenses related to the co-promotion of ACEON® (perindopril erbumine ... -Yahoo! News

Heart-Failure Drug May Cut Vascular Disease Risk (Update1)  Aug 11, 2006
The drugs prescribed in the three original trials were King Pharmaceuticals Inc.'s Altace, Solvay SA's Aceon and Abbott Laboratories' Mavik. ... -Bloomberg

Heart Failure Drugs Good for Heart  Aug 11, 2006
Patients enrolled in the three trials of the study were administered three different drugs – Altace, Aceon and Mavik respectively. ... -HeartZine

Biotech Portfolio Overview: PDL Biopharm Still Cheap, CV ...  Aug 6, 2006
Their two lead drugs on the market are Ranexa and Aceon, and they have some other pipeline drugs that don't have anyone excited, along with Regadenoson, a ... -Seeking Alpha

United: Go halfsies  Aug 16, 2006
Other approved medications that can be split are for heart disease: Aceon, Mavik, Univasc, Atacand, Avapro, Benicar, Cozaar and Diovan; for depression, Zoloft ... -Fall River Herald News

Pharmaceuticals violate patent  Aug 1, 2006
Servier markets perindopril as Coversyl. US sales have been licensed to Solvay Pharmaceuticals Inc., which markets the drug as Aceon. (Bloomberg). -Budapest Business Journal

CV Therapeutics to Announce 2006 Second Quarter Financial Results ...  Jul 20, 2006
CV Therapeutics' approved products include Ranexa® (ranolazine extended- release tablets) and ACEON® (perindopril erbumine) Tablets. ... -Yahoo! News

CV Therapeutics Announces MERLIN TIMI-36 Study To Continue As ...  Jul 9, 2006
CV Therapeutics' approved products include Ranexa(R) (ranolazine extended-release tablets) and ACEON(R) (perindopril erbumine) Tablets. ... -Medical News Today

CV Therapeutics Announces MERLIN TIMI-36 Study to Continue as ...  Jul 7, 2006
CV Therapeutics' approved products include Ranexa® (ranolazine extended-release tablets) and ACEON® (perindopril erbumine) Tablets. ... -Yahoo! News



International Psychopharmacology Research  May 13, 2006
Perindopril (Aceon) was given to all participants, and indapamide (Lozol) was given to those with neither an indication for nor a contraindication to a diuretic ... - Psychiatric Times

CV Therapeutics Announces Abstract to Be Presented at Heart Rhythm ...  May 5, 2006
CV Therapeutics' approved products include Ranexa(TM) (ranolazine extended-release tablets) and ACEON(R) (perindopril erbumine) Tablets. ... - PharmaLive.com

CV Therapeutics Reports 2006 First Quarter Financial Results  Apr 25, 2006
...the second and third quarters of 2005, other expenses incurred to launch Ranexa(TM) (ranolazine extended-release tablets) and co-promote ACEON(R) (perindopril ... - PR Newswire

CV Therapeutics Reports Option Grants Under Nasdaq Marketplace ...  Apr 18, 2006
...hiring, primarily in connection with its commercialization efforts to promote Ranexa(TM) (ranolazine extended- release tablets) and ACEON(R) (perindopril ... - PharmaLive.com

CV Therapeutics Widens 1Q Loss  Apr 25, 2006
...force recruited in the second and third quarter of 2005 to launch the company's drug Ranexa, a treatment for chronic angina, and to co-promote the drug Aceon. ... - Houston Chronicle

NEWS RELEASE  Apr 18, 2006
...primarily in connection with its commercialization efforts to promote Ranexa(TM) (ranolazine extended- release tablets) and ACEON® (perindopril erbumine ... - Financial News USA

Zacks Bull and Bear of the Day Highlights: CV Therapeutics, Altria ...  Apr 27, 2006
Longer term, the MERLIN study will determine the ultimate success of the drug. Aceon is finally contributing and phase III regadenoson looks promising. ... - Business Wire





CV Therapeutics Launches Ranexa  Mar 24, 2006
CV Therapeutics' approved products include Ranexa(TM) (ranolazine extended-release tablets) and ACEON(R) (perindopril erbumine) Tablets. ... - PR Newswire

BITTER PILL ; It's Hard for the Drug Companies to Swallow, but ...  Mar 16, 2006
Aceon, hypertension; Atacand, hypertension; Avapro, hypertension; Benicar, hypertension; Cardura, hypertension; Celexa, depression; Cozaar, hypertension ... - International News Service

CV Therapeutics Reports 2005 Fourth Quarter and Full Year ...  Mar 1, 2006
...deployment of the Company's national cardiovascular specialty sales force and other product support and awareness programs to co- promote ACEON(R) (perindopril ... - MSN Money

CV Therapeutics fourth-quarter loss widens  Mar 1, 2006
Operating expenses rose 25 percent to $75.5 million, from last year's $60.5 million, due to higher costs from the company's co-promotion of Aceon, its drug for ... - BusinessWeek

UPDATE 1-CV Therapeutics 4th-quarter loss widens  Mar 1, 2006
...pharmacies by the end of March. Marketing costs for its hypertension drug Aceon also weighed on results. CV Therapeutics stock, which had ... - Reuters

CV Therapeutics Announces MERLIN TIMI-36 Study to Continue as ...  09 Feb 2006
CV Therapeutics' approved products include Ranexa(TM) (ranolazine extended-release tablets) and ACEON(R) (perindopril erbumine) Tablets. ... - PR Newswire

FDA Approves Ranexa  Jan 27, 2006
CV Therapeutics' approved products include Ranexa(TM) (ranolazine extended-release tablets) and ACEON® (perindopril erbumine) Tablets. ... - Yahoo! News

CV Therapeutics Appoints Joseph M. Davie, MD, Ph.D. to Board of ...  Jan 13, 2006
CV Therapeutics currently has three programs in commercial or late-stage development: ACEON(R) (perindopril erbumine) Tablets, Ranexa(TM) (ranolazine) and ... - PR Newswire

CV Therapeutics Gets FDA OK To Sell Ranexa In Angina  Jan 30, 2006
CV Therapeutics' sales representatives already have been getting to know cardiovascular doctors through sales of the ACE inhibitor Aceon (perindopril erbumine ... - BioWorld Online (subscription)

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional